Clinical trial
Study Evaluation LXR-623 in Healthy Adults
NCT00379860 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00379860 |
|---|---|
| Title | Study Evaluation LXR-623 in Healthy Adults |
| Official title | A Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of LXR-623 Administered Orally to Healthy Subjects |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy Subjects |
| Intervention type | Drug |
| Interventions | LXR-623 |
| Start date | Oct 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | Sep 25, 2006 |
| Last update posted | Mar 9, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: